Licensing In & Out
End-to-end advisory on licensing in and out — connecting asset owners with the right partners across China, Europe, and North America.
Market Context
Active Partner Landscape
Big Pharma BD teams are systematically scanning for clinical-stage pipeline assets to supplement internal R&D — creating sustained demand for well-positioned licensing opportunities.
Territory-Specific Demand
Regional pharma and mid-size groups increasingly acquire territory-specific rights as an alternative to global deals — expanding the viable partner universe for asset owners.
China as Both Source and Market
Chinese-developed biotech assets are gaining credibility with Western licensees, while Western assets continue to attract strong Chinese licensing interest — creating a genuinely bilateral flow.
What Makes It Complex
- Partner identification — finding licensees whose scientific focus, commercial strategy, and territory priorities align with the asset requires deep sector relationships
- Asset positioning — clinical data, IP position, and competitive landscape must be presented in terms that resonate with BD decision-makers, not just scientists
- Territory structuring — determining optimal carve-outs between global, regional, and ex-China rights materially affects both value and negotiability
- Deal valuation — upfront payments, milestone structures, and royalty tiers vary significantly by indication, stage, and territory — benchmarking requires transaction experience
- Negotiation complexity — licensing term sheets carry more moving parts than M&A; managing multiple variables simultaneously demands disciplined process
Deal Flow Process
Why Beam Reach Partners
Bilateral China–Global Network
Established relationships with Chinese pharma and biotech asset owners, and with Western licensees actively seeking pipeline assets — enabling BRP to operate credibly on both sides of the transaction.
Scientific & Commercial Fluency
Our advisors engage with clinical data, IP position, and competitive landscape with the same rigour as the deal economics — ensuring assets are positioned to withstand scrutiny from technically sophisticated counterparties.
Disciplined Licensing Process
BRP applies investment banking process rigour to licensing mandates — structured outreach, qualified partner selection, and senior-led negotiation from first contact through execution.